A Phase 4 interventional study of Misoprostol and Oxytocin in Postpartum Hemorrhage and Cesarean Section, sponsored by Bagcilar Training and Research Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Bagcilar Training and Research Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Postpartum Hemorrhage with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Postpartum Hemorrhage · Turkey.
Among the 44 studies in Postpartum Hemorrhage with a site in Turkey, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 4, and was the 44th registered.
470 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →4 of the 44 studies in Postpartum Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:
Mehmet Kırıköz · Sites in Turkey
Ages 24+ · Healthy volunteers
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · Sites in Turkey
Ages 18–35 · Women only · Healthy volunteers
Cukurova University · Sites in Turkey
Ages 17–25 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 142 is close to the median of 146 across 361 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 148 across the 34 interventional studies, 88 across the 10 observational. Of the 33 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 44 has an industry lead sponsor. The 10 most frequent:
Bagcilar Training and Research Hospital is the lead sponsor of 56 studies on the registry; 7 are open to participants now.
Bagcilar Training and Research Hospital has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Postpartum Hemorrhage with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07943052Bagcilar Training and Research HospitalIntrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Postpartum Hemorrhage with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, controlled, two-arm study evaluates whether adding intrauterine (uterine cornual) misoprostol 400 mcg to standard oxytocin reduces postpartum blood loss in term women undergoing elective cesarean delivery. Participants are randomized 1:1 to standard oxytocin alone or standard oxytocin plus misoprostol. The primary outcome is the change in hemoglobin and hematocrit from preoperative values to 6, 24 and 48 hours after surgery.
A total of 142 women (71 per group) will be enrolled. The study group receives standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after placental delivery; the control group receives standard oxytocin only. Hemoglobin and hematocrit are measured before surgery and at 6, 24 and 48 hours afterwards, and participants are seen on postoperative day 10 for late complications and adverse events. The surgical team is not masked; participants are not informed of their allocation. An interim safety analysis is planned after 50 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after delivery of the placenta during elective cesarean delivery.
Drug: Misoprostol · Drug: Oxytocin
Standard oxytocin only, according to routine clinical practice, during elective cesarean delivery.
Drug: Oxytocin
Misoprostol 400 mcg (2 x 200 mcg tablets), single dose placed in the uterine cornual region after delivery of the placenta, in addition to standard oxytocin.
Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms).
Change in hemoglobin from preoperative value to postoperative 6, 24 and 48 hours
Hemoglobin (g/dL) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups.
Time frame: Preoperative, and 6, 24 and 48 hours after surgery
Change in hematocrit from preoperative value to postoperative 6, 24 and 48 hours
Hematocrit (%) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups.
Time frame: Preoperative, and 6, 24 and 48 hours after surgery
Need for blood transfusion
Proportion of participants requiring blood transfusion after surgery.
Time frame: From surgery until hospital discharge, up to 48 hours
Need for additional uterotonic or hemostatic intervention
Proportion of participants requiring additional uterotonic agents or other hemostatic interventions.
Time frame: During surgery and until hospital discharge, up to 48 hours
Late postoperative complications and readmission
Late complications and hospital readmission assessed at the postoperative day 10 visit.
Time frame: Up to postoperative day 10
Misoprostol-related adverse events
Adverse events potentially related to misoprostol (e.g., fever, shivering, nausea, vomiting, diarrhea) recorded in both groups.
Time frame: Up to postoperative day 10
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
Of 27 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 20. This study's planned 7 months is below that.
Counting every sponsor, half of 28 studies reached it within 12 months; a quarter within 10 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bagcilar Training and Research Hospital